Importer of Controlled Substances Application: Fisher Clinical Services, Inc., 28663 [2018-13224]
Download as PDF
<![CDATA[
28663
Federal Register / Vol. 83, No. 119 / Wednesday, June 20, 2018 / Notices
may also be obtained by accessing its
website (https://www.usitc.gov). Persons
with mobility impairments who will
need special assistance in gaining access
to the Commission should contact the
Office of the Secretary at 202–205–2000.
Background: All dates and other
information relating to this investigation
remain the same as in the Commission’s
notice of investigation and public
hearing issued on May 23, 2018 and
published in the Federal Register of
May 25, 2018 (83 FR 24342).
By order of the Commission.
Issued: June 14, 2018.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2018–13176 Filed 6–19–18; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Fisher Clinical Services,
Inc.
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before July 20, 2018. Such persons
may also file a written request for a
hearing on the application on or before
July 20, 2018.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
DATES:
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/LJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DRW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.34(a), this is notice that on March
16, 2018, Fisher Clinical Services, Inc.,
7554 Schantz Road, Allentown,
Pennsylvania 18106 applied to be
registered as an importer of 1-[1-(2Thienyl)cyclohexyl]pyrrolidine (7473),
a basic class of controlled substance
listed in schedule I.
The company plans to import the
controlled substance in finished dosage
form for testing and clinical trials
purposes only.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under to 21 U.S.C.
952(a)(2). Authorization will not extend
to the import of FDA approved or nonapproved finished dosage forms for
commercial sale.
Dated: June 12, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018–13224 Filed 6–19–18; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Bulk Manufacturer of Controlled
Substances Registration
ACTION:
Registrants listed below have
applied for and been granted
registration by the Drug Enforcement
Administration (DEA) as bulk
manufacturers of various classes of
schedule I and II controlled substances.
SUPPLEMENTARY INFORMATION: The
companies listed below applied to be
registered as bulk manufacturers of
various basic classes of controlled
substances. Information on previously
published notices is listed in the table
below. No comments or objections were
submitted for these notices.
SUMMARY:
Company
FR Docket
sradovich on DSK3GMQ082PROD with NOTICES
AMRI Rensselaer, Inc ....................................................................................................................................
Stepan Company ...........................................................................................................................................
Research Triangle Institute ............................................................................................................................
Rhodes Technologies ....................................................................................................................................
Synthcon, LLC ...............................................................................................................................................
National Center for Natural Products—Research NIDA MPROJECT ..........................................................
Insys Manufacturing LLC ...............................................................................................................................
Navinta LLC ...................................................................................................................................................
The DEA has considered the factors in
21 U.S.C. 823(a) and determined that
the registration of these registrants to
manufacture the applicable basic classes
of controlled substances is consistent
with the public interest and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971. The DEA
investigated each of the company’s
maintenance of effective controls
VerDate Sep<11>2014
17:58 Jun 19, 2018
Jkt 244001
against diversion by inspecting and
testing each company’s physical
security systems, verifying each
company’s compliance with state and
local laws, and reviewing each
company’s background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the DEA has granted a
registration as a bulk manufacturer to
the above listed companies.
PO 00000
Frm 00057
Notice of registration.
Fmt 4703
Sfmt 9990
83 FR 5808
83 FR 9029
83 FR 10523
83 FR 12407
83 FR 13141
83 FR 13522
83 FR 13522
83 FR 13521
Published
February 9, 2018.
March 2, 2018.
March 9, 2018.
March 21, 2018.
March 27, 2018.
March 29, 2018.
March 29, 2018.
March 29, 2018.
Dated: June 12, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018–13223 Filed 6–19–18; 8:45 am]
BILLING CODE 4410–09–P
E:\FR\FM\20JNN1.SGM
20JNN1
]]>Agencies
[Federal Register Volume 83, Number 119 (Wednesday, June 20, 2018)]
[Notices]
[Page 28663]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-13224]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Importer of Controlled Substances Application: Fisher Clinical
Services, Inc.
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration on or before July 20, 2018. Such
persons may also file a written request for a hearing on the
application on or before July 20, 2018.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DRW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
requests for hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/LJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DRW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The Attorney General has delegated his
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, dispensers, importers, and exporters of
controlled substances (other than final orders in connection with
suspension, denial, or revocation of registration) has been redelegated
to the Assistant Administrator of the DEA Diversion Control Division
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0,
appendix to subpart R.
In accordance with 21 CFR 1301.34(a), this is notice that on March
16, 2018, Fisher Clinical Services, Inc., 7554 Schantz Road, Allentown,
Pennsylvania 18106 applied to be registered as an importer of 1-[1-(2-
Thienyl)cyclohexyl]pyrrolidine (7473), a basic class of controlled
substance listed in schedule I.
The company plans to import the controlled substance in finished
dosage form for testing and clinical trials purposes only.
Approval of permit applications will occur only when the
registrant's business activity is consistent with what is authorized
under to 21 U.S.C. 952(a)(2). Authorization will not extend to the
import of FDA approved or non-approved finished dosage forms for
commercial sale.
Dated: June 12, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018-13224 Filed 6-19-18; 8:45 am]
BILLING CODE 4410-09-P
